SYSTEMIC SCLEROSIS (SSC)

This early-phase study will test a new drug, cizutamig, in 10 adults with systemic sclerosis, a condition that causes skin hardening and organ damage. The main goal is to check if the drug is safe and tolerable, while also looking at how the body processes it and whether it shows…

This early-stage study tests whether a single infusion of a patient's own modified immune cells (CAR-T cells) is safe for people with severe autoimmune diseases like lupus, rheumatoid arthritis, and scleroderma that haven't responded to standard treatments. The study will closely…

This early-stage study tests a new treatment called HN2302 in 12 adults with autoimmune diseases like lupus or scleroderma. The therapy uses the body's own immune cells, modified to target and reduce harmful immune activity. The main goal is to check safety, while also seeing if …

This early-stage study tests a new drug, GB261, in 10 adults with systemic sclerosis, a condition that causes skin and organ hardening. The main goal is to check safety and how the body handles the drug. Researchers will also look for early signs that the drug might help control …

This early-phase study tests BCT301, a therapy made from special stem cells turned into immune cells, for people with hard-to-treat autoimmune diseases like lupus and scleroderma. The main goal is to check safety and find the right dose. Only 10 participants will be enrolled.

This study looks at a blood protein called FAP, which is linked to tissue scarring and inflammation. Researchers will measure FAP levels in people with rheumatoid arthritis, systemic sclerosis (scleroderma), and healthy volunteers. The goal is to see if FAP levels relate to disea…

This study will use a high-tech blood test (mass spectrometry) to look at different immune cells in 500 people with various autoimmune diseases and healthy volunteers. The goal is to find patterns that could help doctors screen for and diagnose these conditions earlier. No new tr…